Cognitive impairment in long-COVID

被引:2
作者
Tozkir, Julide [1 ,3 ]
Turkmen, Cigdem [2 ]
Topcular, Baris [2 ]
机构
[1] Trakya Univ, Hlth Serv Vocat Coll, Balkan Yerleskesi, TR-22030 Edirne, Turkiye
[2] Abbott Prod Operat AG EPD, Basel, Switzerland
[3] Istanbul Florence Nightingale Hosp, Neurol Sci Ctr, Istanbul, Turkiye
来源
IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE | 2024年 / 77卷 / 5-6期
关键词
COVID-19; long-COVID; cognition; cognitive impairment; brain fog; TOOL;
D O I
10.18071/isz.77.0151
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background - Long Covid is a complex condition characterised by symptoms that persist for weeks and months after the Co vid infection, accompanied by cognitive impairment that negatively affects daily life. Understanding this complex condition is important for the development of diagnostic and therapeutic strategies. Purpose - This article aims to provide a comprehensive overview of cognitive impairment in long-COVID, including its definition, symptoms, pathophysiology, risk factors, assessment tools, imaging abnormalities, potential biomarkers, management strategies, long-term outcomes, and future directions for research. Methods - The search methodology used in this review aimed to include a wide range of research on cognitive impairment related to both COVID-19 and long-COVID. Systematic searches of PubMed and Google Scholar databases were conducted using a mixture of MeSH terms and keywords including 'cognition', 'cognitive impairment', 'brain fog', 'COVID-19' and 'long-COVID'. The search was restricted to studies published in English between 1 January 2019 and 11 February 2024, which presented findings on neurological manifestations in human participants. Results - Long-COVID is characterized by persistent symptoms following COVID-19 infection, with cognitive impairment being a prominent feature. Symptoms include brain fog, difficulties with concentration, memory issues, and executive function deficits. Pathophysiological mechanisms involve viral persistence, immune responses, and vascular damage. Risk factors include age, pre-existing conditions, and disease severity. Cognitive assessment tools such as the Montreal Cognitive Assessment (MoCA) are essential for diagnosis. Imaging studies, including MRI, PET, and SPECT, reveal structural and functional brain alterations. Potential biomarkers include C -reactive protein, interleukin-6, and neuron -specific enolase. Management strategies encompass cognitive rehabilitation, occupational therapy, medications, and lifestyle modifications. Discussion - Long-COVID poses a multifaceted challenge, and cognitive impairment significantly impacts patients' lives. A multi- disciplinary approach, including cognitive rehabilitation and medication when appro- priate, is essential for effective management. Future research should focus on validating biomarkers and understanding long-term cognitive outcomes. Conclusion - Long-COVID is a global health concern, and cognitive impairment is a distressing symptom. While pharmacological interventions have potential, they require careful consideration. Continued research is crucial for improving the understanding and treatment of cognitive impairment in long-COVID.
引用
收藏
页数:69
相关论文
共 51 条
[31]   A review of cytokine-based pathophysiology of Long COVID symptoms [J].
Low, Russell N. ;
Low, Ryan J. ;
Akrami, Athena .
FRONTIERS IN MEDICINE, 2023, 10
[32]   Inflammation at the crossroads of COVID-19, cognitive deficits and depression [J].
Lyra e Silva, Natalia M. ;
Barros-Aragao, Fernanda G. Q. ;
De Felice, Fernanda G. ;
Ferreira, Sergio T. .
NEUROPHARMACOLOGY, 2022, 209
[33]   Accelerated cognitive decline after the COVID-19 pandemic in a community population of older persons with cognitive impairment: A 4-year time series analysis in the Tokyo Metropolis area [J].
Matsui, Toshifumi ;
Mitsuma, Sayuri ;
Nagata, Akane ;
Matsushita, Sachio ;
Asahi, Toshiomi .
GERIATRICS & GERONTOLOGY INTERNATIONAL, 2023, 23 (03) :200-204
[34]   Role of endothelial cells and angiotensin converting enzyme-II in COVID-19 and brain damages post-infection [J].
Mehboob, Riffat ;
von Kries, Jens Peter ;
Ehsan, Kashifa ;
Almansouri, Majid ;
Bamaga, Ahmed K. .
FRONTIERS IN NEUROLOGY, 2023, 14
[35]   Cognitive impairments among patients in a long-COVID clinic: Prevalence, pattern and relation to illness severity, work function and quality of life [J].
Miskowiak, K. W. ;
Pedersen, J. K. ;
Gunnarsson, D. V. ;
Roikjer, T. K. ;
Podlekareva, D. ;
Hansen, H. ;
Dall, C. H. ;
Johnsen, S. .
JOURNAL OF AFFECTIVE DISORDERS, 2023, 324 :162-169
[36]   Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables [J].
Miskowiak, K. W. ;
Johnsen, S. ;
Sattler, S. M. ;
Nielsen, S. ;
Kunalan, K. ;
Rungby, J. ;
Lapperre, T. ;
Porsberg, C. M. .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 46 :39-48
[37]   Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019 [J].
Miyazato, Yusuke ;
Morioka, Shinichiro ;
Tsuzuki, Shinya ;
Akashi, Masako ;
Osanai, Yasuyo ;
Tanaka, Keiko ;
Terada, Mari ;
Suzuki, Michiyo ;
Kutsuna, Satoshi ;
Saito, Sho ;
Hayakawa, Kayoko ;
Ohmagari, Norio .
OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (11)
[38]   The montreal cognitive assessment, MoCA:: A brief screening tool for mild cognitive impairment [J].
Nasreddine, ZS ;
Phillips, NA ;
Bédirian, V ;
Charbonneau, S ;
Whitehead, V ;
Collin, I ;
Cummings, JL ;
Chertkow, H .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (04) :695-699
[39]   Magnetic Resonance Imaging Scan of the Brain After Mild COVID-19 Infection [J].
Ohtake, Makoto ;
Suenaga, Jun ;
Akimoto, Taisuke ;
Ikeuchi, Hisataro ;
Muroya, Ayumu ;
Ohata, Hiroyuki ;
Kubota, Yoshihiro ;
Chiku, Masaaki ;
Hamano, Tomoaki ;
Yamamoto, Tetsuya .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
[40]   Imaging and neuropathological findings in patients with Post COVID-19 Neurological Syndrome-A review [J].
Okrzeja, Jakub ;
Garkowski, Adam ;
Kubas, Bozena ;
Moniuszko-Malinowska, Anna .
FRONTIERS IN NEUROLOGY, 2023, 14